Context Therapeutics Inc. (NASDAQ: CNTX) announced interim results from its ongoing Phase 1 clinical trial of CTIM-76, a bispecific antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE